BKV vs. KNSA

Last updated Jun 24, 2026

BKV (BKV Corp) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. BKV operates in Oil & Gas E&P (Energy), while KNSA operates in Biotechnology (Healthcare). Over the past year, BKV returned 6.21% vs 107.14% for KNSA. At a 0.10 correlation, their price movements are largely independent.

Performance

BKV vs. KNSA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BKV Corp (BKV) and Kiniksa Pharmaceuticals, Ltd. (KNSA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BKV achieves a -6.11% return, which is significantly lower than KNSA's 44.22% return.

BKV

• 1D: -0.78%
• 1M: -9.90%
• YTD: -6.11%
• 6M: -8.31%
• 1Y: 6.21%
• 3Y*: —
• 5Y*: —
• 10Y*: —

KNSA

• 1D: 4.13%
• 1M: 11.74%
• YTD: 44.22%
• 6M: 39.91%
• 1Y: 107.14%
• 3Y*: 56.70%
• 5Y*: 32.13%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BKV vs. KNSA - Yearly Performance Comparison

	2026 (YTD)	2025	2024
BKV BKV Corp	-6.11%	14.17%	28.19%
KNSA Kiniksa Pharmaceuticals, Ltd.	44.22%	108.54%	-17.93%

Correlation

The correlation between BKV and KNSA is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (All Time) Calculated using the full available price history since Sep 26, 2024	0.10

Fundamentals

Market Cap BKV : $2.61B KNSA : $4.90B
EPS BKV : $3.24 KNSA : $0.92
PE Ratio BKV : 7.87 KNSA : 64.60
PS Ratio BKV : 2.15 KNSA : 6.26
PB Ratio BKV : 1.13 KNSA : 8.09
Total Revenue (TTM) BKV : $1.08B KNSA : $754.05M
Gross Profit (TTM) BKV : $693.49M KNSA : $294.06M
EBITDA (TTM) BKV : $544.16M KNSA : $101.06M

Return for Risk

BKV vs. KNSA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BKV

BKV Risk / Return Rank: 47
BKV Sharpe Ratio Rank: 48
BKV Sortino Ratio Rank: 44
BKV Omega Ratio Rank: 43
BKV Calmar Ratio Rank: 49
BKV Martin Ratio Rank: 49

KNSA

KNSA Risk / Return Rank: 93
KNSA Sharpe Ratio Rank: 93
KNSA Sortino Ratio Rank: 93
KNSA Omega Ratio Rank: 91
KNSA Calmar Ratio Rank: 92
KNSA Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BKV vs. KNSA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BKV Corp (BKV) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BKV	KNSA	Difference
Sharpe ratio: Return per unit of total volatility	0.14	2.49	-2.35
Sortino ratio: Return per unit of downside risk	0.50	3.52	-3.02
Omega ratio: Gain probability vs. loss probability	1.06	1.44	-0.37
Calmar ratio: Return relative to maximum drawdown	0.25	5.10	-4.85
Martin ratio: Return relative to average drawdown	0.58	17.99	-17.40

BKV vs. KNSA - Sharpe Ratio Comparison

The current BKV Sharpe Ratio is 0.14, which is lower than the KNSA Sharpe Ratio of 2.49. The chart below compares the historical Sharpe Ratios of BKV and KNSA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BKV vs. KNSA - Drawdown Comparison

The maximum BKV drawdown since its inception was -39.98%, smaller than the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for BKV and KNSA.

Drawdown Indicators

	BKV	KNSA	Difference
Max Drawdown Largest peak-to-trough decline	-39.98%	-83.06%	+43.08%
Max Drawdown (1Y) Largest decline over 1 year	-24.97%	-21.12%	-3.85%
Max Drawdown (3Y) Largest decline over 3 years	—	-34.14%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-53.17%	—
Current Drawdown Current decline from peak	-20.74%	0.00%	-20.74%
Average Drawdown Average peak-to-trough decline	-11.68%	-40.57%	+28.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.65%	5.98%	+4.67%

Volatility

BKV vs. KNSA - Volatility Comparison

The current volatility for BKV Corp (BKV) is 10.62%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 11.38%. This indicates that BKV experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BKV	KNSA	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.62%	11.38%	-0.76%
Volatility (6M) Calculated over the trailing 6-month period	26.53%	34.38%	-7.85%
Volatility (1Y) Calculated over the trailing 1-year period	43.66%	43.30%	+0.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.33%	53.49%	-10.16%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	43.33%	63.93%	-20.60%

Dividends

BKV vs. KNSA - Dividend Comparison

Neither BKV nor KNSA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

BKV vs. KNSA - Profitability Comparison

The chart below illustrates the profitability comparison between BKV Corp and Kiniksa Pharmaceuticals, Ltd. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BKV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BKV Corp reported a gross profit of 405.49M and revenue of 432.85M. Therefore, the gross margin over that period was 93.7%.

KNSA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.

BKV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BKV Corp reported an operating income of 86.03M and revenue of 432.85M, resulting in an operating margin of 19.9%.

KNSA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.

BKV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BKV Corp reported a net income of 44.08M and revenue of 432.85M, resulting in a net margin of 10.2%.

KNSA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.

Frequently Asked Questions

Can I hold both BKV and KNSA in my portfolio?

BKV and KNSA have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BKV or KNSA?

KNSA has higher volatility (11.38%) compared to BKV (10.62%). In terms of maximum drawdown, BKV dropped -39.98% vs KNSA's -83.06%.

Which has better risk-adjusted returns?

KNSA currently has the higher Sharpe Ratio (2.49 vs 0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.